Profil
Mátyás Végh served as the Chief Executive Officer of The Genetics Co., Inc. from 2002 to 2009.
He then became the Chief Executive Officer of Creoptix AG.
Later, he worked as the Managing Partner at Nextech Invest AG from 2010 to 2012.
Végh holds an MBA from the University of St. Gallen, an undergraduate degree from the University of Basel, and a doctorate from the University of Zurich.
Anciens postes connus de Mátyás Végh
| Sociétés | Poste | Fin |
|---|---|---|
Nextech Invest AG
 Nextech Invest AG Investment ManagersFinance Nextech Invest AG (Nextech) is an independent venture capital firm with headquarters in Zurich, Switzerland. It was founded by Alfred Scheidegger in 1998. Nextech's investors include public pension funds, banks, asset management companies and Swiss and German high-net worth individuals. | Private Equity Investor | 28/02/2012 |
The Genetics Co., Inc.
 The Genetics Co., Inc. Medical/Nursing ServicesHealth Services The Genetics Company is a privately held drug discovery and development company active in the areas of cancer and neurodegenerative diseases. The company has identified small molecule inhibitors of two proprietary targets with in the Wnt-pathway, which is believed to play a crucial role in colon cancer. It has also identified small molecule inhibitors of BACE (beta-amyloid converting enzyme). In parallel, the company has identified and is in the process of further characterizing a series of novel growth-related drug target candidate genes for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the company currently has 29 employees. The Genetics Company offers you a range of high quality products to analyze Amyloid beta peptides x-40 and x-42 for basic research but also for pre-clinical and clinical development and in vitro diagnostics (IVD). Its CE-certified ELISA kits are the only clinically validated products for the determination of the Abeta42/40-Ratio in human CSF. These kits enable the early diagnosis of incipient Alzheimer's disease and can be used for patient stratification and monitoring in clinical trials of Alzheimer drug candidates. | President | 01/01/2010 |
Creoptix AG
 Creoptix AG BiotechnologyHealth Technology Creoptix AG provides biosensor devices for applications in drug discovery. It specializes in optical instruments and consumables for the label-free analysis of molecular interactions for the drug discovery. The firm’s products include instruments, sensors, and software. The company was founded by Kaspar Cottier in 2009 and is headquartered in Wadenswil, Switzerland. | Directeur Général | - |
Formation de Mátyás Végh
| University of Basel | Undergraduate Degree |
| University of Zurich | Doctorate Degree |
| University of St. Gallen | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
The Genetics Co., Inc.
The Genetics Co., Inc. Medical/Nursing ServicesHealth Services The Genetics Company is a privately held drug discovery and development company active in the areas of cancer and neurodegenerative diseases. The company has identified small molecule inhibitors of two proprietary targets with in the Wnt-pathway, which is believed to play a crucial role in colon cancer. It has also identified small molecule inhibitors of BACE (beta-amyloid converting enzyme). In parallel, the company has identified and is in the process of further characterizing a series of novel growth-related drug target candidate genes for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the company currently has 29 employees. The Genetics Company offers you a range of high quality products to analyze Amyloid beta peptides x-40 and x-42 for basic research but also for pre-clinical and clinical development and in vitro diagnostics (IVD). Its CE-certified ELISA kits are the only clinically validated products for the determination of the Abeta42/40-Ratio in human CSF. These kits enable the early diagnosis of incipient Alzheimer's disease and can be used for patient stratification and monitoring in clinical trials of Alzheimer drug candidates. | Health Services |
Nextech Invest AG
Nextech Invest AG Investment ManagersFinance Nextech Invest AG (Nextech) is an independent venture capital firm with headquarters in Zurich, Switzerland. It was founded by Alfred Scheidegger in 1998. Nextech's investors include public pension funds, banks, asset management companies and Swiss and German high-net worth individuals. | Finance |
Creoptix AG
Creoptix AG BiotechnologyHealth Technology Creoptix AG provides biosensor devices for applications in drug discovery. It specializes in optical instruments and consumables for the label-free analysis of molecular interactions for the drug discovery. The firm’s products include instruments, sensors, and software. The company was founded by Kaspar Cottier in 2009 and is headquartered in Wadenswil, Switzerland. | Health Technology |